Digene strengthens diagnostic patents:
This article was originally published in Clinica
US diagnostics company Digene has received a European patent for its Hybrid Capture technology. All of the company's tests are based on this technology, which uses signal amplification to detect as few as 100 molecules of DNA or RNA in a rapid format. The patent strengthens the company's protection for its human papillomavirus products and core technology, according to Beltsville, Maryland-based Digene.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.